Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study

BackgroundValidity is the ability of an instrument to measure what it claims to measure. It means the degree to which the empirical evidence supports the trustworthiness of interpretations based on the calculated scores. The hematological malignancy (HM) specific patient reported outcome measure (HM...

Full description

Bibliographic Details
Main Authors: Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton, Magda J. Al-Obaidi, Metod Oblak, Sam Salek
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Pharmacology
Subjects:
hematological malignancy
HM-PRO
quality of life
symptoms
construct validity
clinical practice
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01308/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.01308/full

Similar Items